Name of Patient: Abdullah Saud

Age: 27

Medical Condition: lung cancer

DRUG STUDY

Drug Name/Generic Classification Dosage Action/Indication/Contraindication Side Effects/Adverse Reactions Nursing

Name Responsibilities
Protein-bound Actions: Side effects: 1. Monitor for
Brand name: paclitaxel also Injection, Abraxane is a microtubule inhibitor hypersensitivity
- Abraxane known as powder, Black, tarry stools
that promotes the assembly of  reactions,
nanoparticle lyophilized, microtubules from tubulin dimers  bloating or swelling of the especially during
albumin–bound for
paclitaxel or and stabilizes microtubules by face, arms, hands, lower legs, first and second
suspension
nab-paclitaxel, is preventing depolymerization. This or feet administrations of
100
an injectable stability results in the inhibition of  blurred or double vision the Abraxane. S&S
Generic name: mg/20mL
formulation of the normal dynamic reorganization  chest pain requiring
- Nab-paclitaxel paclitaxel used chills
of the microtubule network that is  treatment, but not
to treat breast
essential for vital interphase and  cough necessarily
cancer, lung
cancer and mitotic cellular functions. Paclitaxel  fever discontinuation of
pancreatic induces abnormal arrays (or  loss of taste the drug, include
cancer, among bundles) of microtubules  lower back or side pain dyspnea,
Picture of the drug: others. throughout the cell cycle and  painful or difficult urination hypotension, and
Paclitaxel kills multiple asters of microtubules  pale skin chest pain.
cancer cells by rapid weight gain
during mitosis.  Discontinue
preventing the
normal  sneezing immediately and
breakdown of Indications:  sore mouth, tongue, or throat manage symptoms
microtubules Abraxane is indicated for the  tightness in the chest aggressively if
during cell treatment of metastatic breast cancer  tingling of the hands or feet angioedema and
division. In this in adult patients who have failed first-  troubled breathing with generalized
formulation, line treatment for metastatic disease exertion urticaria develop.
paclitaxel is and for whom standard, anthracycline
bonded to
 ulcers, sores, or white spots in 2. Monitor vital signs
containing therapy is not indicated
albumin as a the mouth frequently,
(see section 4.4).
delivery vehicle.  unusual bleeding or bruising especially during
It is Abraxane in combination with  unusual weight gain or loss the first hour of
manufactured gemcitabine is indicated for the first-  unusual tiredness or weakness infusion.
and sold in the line treatment of adult patients with Bradycardia occurs
United States by metastatic adenocarcinoma of the Adverse Reactions: in approximately
Celgene under pancreas.  nausea, 12% of patients,
the trade name
Abraxane Abraxane in combination with  vomiting, usually during
where it is carboplatin is indicated for the first-  indigestion, infusion. It does
designated as line treatment of non-small cell lung  diarrhea, not normally
an orphan drug cancer in adult patients who are not  mouth sores, require treatment.
as first-line candidates for potentially curative  headache, Cardiac monitoring
treatment, in surgery and/or radiation therapy.  muscle or joint pain, is indicated for
combination with
gemcitabine, for Contra-indications:  numbness/tingling/burning of those with severe
the orphan The following conditions are the hands or feet, conduction
disease contraindicated with this drug.  weakness, abnormalities.
"metastatic Conditions:  dizziness, 3. Lab tests: Monitor
adenocarcinoma  infections, hematologic status
of the pancreas.
 a bad infection
 decreased function of bone  anemia, or throughout course
marrow  temporary hair loss. of treatment.
 anemia Severe neutropenia
 decreased blood platelets is common but
 a painful condition that usually of short
affects the nerves in the legs duration (less than
and arms called peripheral 500/mm3 for less
neuropathy than 7 d) with the
 a heart attack nadir occurring
 slow heartbeat about day 11.
 abnormal heart rhythm Thrombocytopenia
 low blood pressure occurs less often
and is less severe
 liver problems
with the nadir
 high amount of bilirubin in
around day 8 or 9.
the blood
The incidence and
 abnormal liver function
severity of anemia
tests
increase with
 pregnancy
exposure to
 a mother who is producing
paclitaxel.
milk and breastfeeding
 a significant drop in a
 certain type of white blood 4. Monitor for
cell called a neutrophil peripheral
Allergies: neuropathy, the
Paclitaxel severity of which is
Paclitaxel/Docetaxel dose dependent.
Severe symptoms
occur primarily
with higher than
recommended
doses.

Name of Student: Amal Fahad Mark: ________________________

Date of Submission: 24- 11-2019 Instructor’s Signature: ___________

References:
1. Immunisation against infectious disease: Chapter 6: General contraindications to vaccination Public
Health England
First published: March 2013 and regularly updated on the Gov.UK website

2. "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. February 2,
2011.
http://www.cancer.gov/dictionary?CdrID=507751

3. "FDA approves Celgene's Abraxane for lung cancer". Reuters. October 12, 2012.
https://www.reuters.com/article/2012/10/12/us-celgene-abraxane-idUSBRE89B0SQ20121012

4. Pollack, Andrew (September 7, 2013). "F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer". New York
Times. Retrieved September 6, 2013.
https://www.nytimes.com/2013/09/07/business/fda-approves-drug-for-late-stage-pancreatic-cancer.html

5. "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. 2006.
http://www.cancer.gov/cancertopics/druginfo/nanoparticlepaclitaxel

6. "Abraxane". Orpha Net. September 6, 2013. Retrieved July 20, 2015.

http://www.orpha.net/consor

7. "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. 2006.

http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel

8. "Paclitaxel (Abraxane)". U.S. Food and Drug Administration. October 11, 2012. Retrieved 10 December 2012.
"Resolution 9190". Australian Drug Evaluation Committee. June 6, 2008.
http://www.tga.gov.au/archive/committees-adec-resolutions-0258.htm